Starpharma Holdings Ltd (ASX: SPL) Share Price and News
Price
$0.094
Movement
0.00 (0.0)
as at 6 May - Closed (20 mins delayed)
52 Week Range
$0.086 - $0.13
1 Year Return
-24.8%
Starpharma Holdings Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$39.31 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
418.22 million
Earnings per share
-0.031
Dividend per share
N/A
Year To Date Return
-16.36%
Earnings Yield
N/A
Franking
-
Share Price
$0.094
Day Change
0.00 (0.0)
52 Week Range
$0.086 - $0.13
Yesterday's Close
$0.094
Today's Open
$0.093
Days Range
$0.091 - $0.094
Volume
65,859
Avg. Volume (1 month)
184,798
Turnover
$6,137
as at 6 May - Closed
Starpharma Holdings Ltd (ASX: SPL)
Latest News
Healthcare Shares
Starpharma (ASX:SPL) share price jumps 6% following AGM
Share Fallers
Why is the Starpharma (ASX:SPL) share price trading at 52-week lows?
Healthcare Shares
Starpharma (ASX:SPL) share price lifts on supply and distribution deal
Share Gainers
Why Fletcher Building, Magellan, Sezzle, & Starpharma are racing higher
Share Gainers
Here's why the Starpharma (ASX:SPL) share price is charging 4% higher today
Healthcare Shares
These were the best performing ASX biotech shares in September
Share Market News
Starpharma (ASX:SPL) share price surges 5% on United States patent news
Share Gainers
Why Accent, Calix, Pilbara Minerals, & Starpharma shares are racing higher
Earnings Results
Starpharma (ASX:SPL) share price tanks 3% on 67% revenue drop
Share Market News
Why the Starpharma (ASX:SPL) share price raced higher today
Share Market News
Starpharma (ASX:SPL) share price sinks 5% despite new board member
Share Gainers
Why the Starpharma (ASX:SPL) share price is racing 7% higher today
Frequently Asked Questions
-
No, Starpharma does not pay dividends at this time.
-
Starpharma listed on the ASX on 28 September 2000.
SPL ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| 30th Apr 2025 2025-04-30T09:33:43 | Quarterly Activities/Appendix 4C Cash Flow Report | YesNo | 9:33am | 8 | 703k |
| 4th Apr 2025 2025-04-04T10:05:39 | Notification of cessation of securities - SPL | YesNo | 10:05am | 4 | 13k |
| 4th Apr 2025 2025-04-04T10:02:29 | Application for quotation of securities - SPL | YesNo | 10:02am | 6 | 16k |
| 17th Mar 2025 2025-03-17T16:12:46 | Becoming a substantial holder | YesNo | 4:12pm | 4 | 150k |
| 26th Feb 2025 2025-02-26T09:44:19 | Half Yearly Report and Accounts | YesNo | 9:44am | 21 | 2.5M |
| 29th Jan 2025 2025-01-29T10:16:51 | Quarterly Activities/Appendix 4C Cash Flow Report | YesNo | 10:16am | 7 | 278k |
| 16th Jan 2025 2025-01-16T14:58:06 | DEP Presentation at Targeted Radio Therapies Conference | YesNo | 2:58pm | 28 | 2.5M |
| 19th Dec 2024 2024-12-19T09:41:53 | SPL receives positive FDA feedback on DEP SN38 for PROC | YesNo | 9:41am | 3 | 171k |
| 12th Dec 2024 2024-12-12T09:40:16 | Change of Director's Interest Notice - Ms Cheryl Maley | YesNo | 9:40am | 2 | 298k |
| 12th Dec 2024 2024-12-12T09:26:16 | Notification regarding unquoted securities - SPL | YesNo | 9:26am | 6 | 17k |
About Starpharma Holdings Ltd
Starpharma Holdings Ltd (ASX: SPL) is an Australian biotechnology company involved in the development of dendrimer products for pharmaceutical, life science, and other applications.
Dendrimers are synthetically manufactured, nanoscale molecules, particularly useful to the pharmaceutical industry for their unique properties as carriers of other molecular structures.
Starpharma describes itself as a world leader in the field. The company is developing programs for drug delivery applications, the treatment of respiratory viruses, and its VivaGel product.
VivaGel can be used for the management and prevention of bacterial vaginosis and as a coating for condoms. The company's VIRALEZE product is an antiviral nasal spray approved for use in many countries, including Europe and the UK.
SPL Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 05 May 2025 | $0.09 | $0.00 | 0.00% | 24,168 | $0.09 | $0.09 | $0.09 |
| 02 May 2025 | $0.09 | $0.00 | 0.00% | 25,000 | $0.09 | $0.09 | $0.09 |
| 01 May 2025 | $0.09 | $0.00 | 0.00% | 43,456 | $0.09 | $0.09 | $0.09 |
| 30 Apr 2025 | $0.09 | $0.00 | 0.00% | 118,453 | $0.09 | $0.09 | $0.09 |
| 29 Apr 2025 | $0.09 | $0.00 | 0.00% | 167,134 | $0.09 | $0.09 | $0.09 |
| 28 Apr 2025 | $0.09 | $0.01 | 11.24% | 181,875 | $0.09 | $0.09 | $0.09 |
| 24 Apr 2025 | $0.09 | $-0.01 | -10.31% | 812,561 | $0.09 | $0.09 | $0.09 |
| 23 Apr 2025 | $0.10 | $0.00 | 0.00% | 39,272 | $0.10 | $0.10 | $0.10 |
| 22 Apr 2025 | $0.09 | $0.00 | 0.00% | 277,385 | $0.10 | $0.10 | $0.09 |
| 17 Apr 2025 | $0.10 | $0.00 | 0.00% | 67,378 | $0.10 | $0.10 | $0.10 |
| 16 Apr 2025 | $0.10 | $0.00 | 0.00% | 202,222 | $0.10 | $0.10 | $0.10 |
| 15 Apr 2025 | $0.10 | $0.00 | 0.00% | 311,093 | $0.10 | $0.10 | $0.10 |
| 14 Apr 2025 | $0.10 | $0.00 | 0.00% | 15,014 | $0.10 | $0.10 | $0.10 |
| 11 Apr 2025 | $0.10 | $0.00 | 0.00% | 5,014 | $0.10 | $0.10 | $0.10 |
| 10 Apr 2025 | $0.10 | $0.00 | 0.00% | 290,473 | $0.10 | $0.10 | $0.10 |
| 09 Apr 2025 | $0.10 | $0.01 | 10.99% | 3,885 | $0.10 | $0.10 | $0.09 |
| 08 Apr 2025 | $0.09 | $0.00 | 0.00% | 24,735 | $0.09 | $0.09 | $0.09 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 11 Dec 2024 | Cheryl Maley | Issued | 5,202,703 | $598,310 |
Issue of securities. 7,401,386 Performance Rights, As per announcement on 12-12-2024
|
| 05 Nov 2024 | Robert Thomas | Buy | 300,000 | $28,000 |
On-market trade.
|
| 23 Oct 2024 | Robert Thomas | Buy | 200,000 | $18,500 |
On-market trade.
|
| 23 Oct 2024 | Robert Thomas | Buy | 300,000 | $27,750 |
On-market trade.
|
| 13 Sep 2024 | Russell Basser | Buy | 200,000 | $18,600 |
On-market trade.
|
| 02 Sep 2024 | David McIntyre | Buy | 405,886 | $3,879 |
On-market trade. As per announcement on 02-09-2024
|
| 02 Sep 2024 | Robert Thomas | Buy | 350,000 | $3,246 |
On-market trade.
|
| 28 Jun 2024 | Jeff Davies | Buy | 879,687 | $79,699 |
On-market trade.
|
| 26 Jun 2024 | Robert Thomas | Buy | 200,000 | $17,800 |
On-market trade.
|
| 25 Jun 2024 | Lynda Cheng | Buy | 110,555 | $9,950 |
On-market trade.
|
| 20 Jun 2024 | Robert Thomas | Buy | 250,000 | $22,679 |
On-market trade.
|
| 30 May 2024 | Cheryl Maley | Buy | 125,000 | $14,065 |
On-market trade.
|
| 29 May 2024 | Robert Thomas | Buy | 150,000 | $17,750 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Robert Bain Thomas | Non-Executive DirectorNon-Executive Chairman | Dec 2013 |
Mr Thomas has background in financial services and capital markets and is a non-executive director of several Australian listed companies. He was previously a Partner of Potter Partners (now UBS), where he was also Head of Research. He is a member of Risk Committee.
|
| Ms Cheryl Ann Maley | Chief Executive OfficerManaging Director | Jan 2024 |
Ms Maley has over 25 years of experience in the pharmaceutical industry, including 20 years in leadership roles at well-known and leading organisations, including Novartis and AbbVie. Her previous roles include nine years at Novartis in senior commercial and executive roles and various sales and marketing positions with AbbVie/Abbott, Servier Laboratories, and Wyeth Pharmaceuticals.
|
| Mr David McIntyre | Non-Executive Director | Mar 2020 |
Mr McIntyre has more than 20 years of executive experience including 18 years in the life sciences sector, having held various C-suite level roles at Tessa Therapeutics, Inc., AVITA Therapeutics, Inc., HeartWare International, Inc., and Braeburn, Inc. He is the Chair of Risk Committee.
|
| Ms Lynda Cheng | Non-Executive Director | Aug 2021 |
Ms Cheng has over 25 years of experience as a finance executive, including substantial international experience and several non-executive directorships, Ms Cheng's experience covers the majority of key areas described in Starpharma's Board skills matrix. In particular, she has expertise in accounting/corporate finance, audit and risk; M&A/capital markets; strategy and risk management; governance; as well as business development. Ms Cheng has had involvement in the commercialisation of new innovations during her tenure at South East Water and also while working with disruptive technology companies in Silicon Valley. She is a member of Risk Committee.
|
| Dr Jeff Davies | Non-Executive Director | Apr 2022 |
Dr Davies has over 35 years of experience within the biopharmaceutical industry, Dr Davies is an accomplished executive skilled in R&D, product development and commercialisation strategy, business development, manufacturing and clinical and regulatory affairs. Dr Davies has leadership skills and experience in commercialising scientific research for healthcare products.
|
| Dr Russell Basser | Non-Executive Director | Feb 2023 |
Dr Basser has over 20 years of executive experience in the biotechnology industry and 10 years as a practicing clinical oncologist, Dr Basser has leadership skills and experience in healthcare/scientific research; pharmaceutical product development; international executive experience and skills in regulation/public policy; commercialisation of innovation; business development; governance; strategy; and risk management.
|
| Mr Justin Cahill | Chief Financial OfficerCompany Secretary | Apr 2023 |
-
|
| Justin Cahill | Chief Financial OfficerCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 81,247,474 | 19.70% |
| JP Morgan Nominees Australia PTY Limited | 31,174,308 | 7.56% |
| Citicorp Nominees Pty Limited | 15,203,959 | 3.69% |
| BNP Paribas Noms Pty Ltd | 14,494,331 | 3.51% |
| Bell Potter Nominees Ltd <Bb Nominees A/C> | 9,000,000 | 2.18% |
| Ingot Capital Investments Pty Ltd | 8,705,000 | 2.11% |
| T & N Argyrides Investments P/L <T & N Argyrides Pension A/C> | 5,060,000 | 1.23% |
| BNP Paribas Nominees Pty Ltd <Clearstream> | 4,866,370 | 1.18% |
| Mr Kingsley Bryan Bartholomew | 4,612,025 | 1.12% |
| Lavya Pty Ltd <Lavya Family A/C> | 4,344,628 | 1.05% |
| BNP Paribas Nominees Pty Ltd <Agency Lending A/C> | 4,267,008 | 1.03% |
| HSBC Custody Nominees (Australia) Limited A/C 2 | 4,141,107 | 1.00% |
| Mr Peter Murray Jackson | 3,921,959 | 0.95% |
| E Equities Pty Ltd | 3,700,000 | 0.90% |
| All States Finance Pty Limited | 3,500,000 | 0.85% |
| Applecross Secretarial Services Pty Ltd <L Gorr Family A/C> | 3,361,550 | 0.82% |
| Ms Jacinth Fairley | 3,252,386 | 0.79% |
| Charles & Cornelia Goode Foundation Pty Ltd <CCG Foundation A/C> | 3,200,000 | 0.78% |
| Mr Thomas Argyrou | 3,000,000 | 0.73% |
| BNP Paribas Nominees Pty Ltd <IB AU Noms Retail Client> | 2,739,822 | 0.66% |